A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants

Exclusion Criteria

• •Healthy Participants:
• •Currently participating in another study, or within 5 half-lives/3 months of the last dose of a previous investigational product.
• •Presence diseases (cardiovascular, neurological, renal, immunological, metabolic, etc.) or malignant tumors.- Major surgery or severe trauma within the past 6 months.
• •Acute infection (e.g., influenza, gastroenteritis) within 14 days; vaccination within 28 days prior to screening.
• •Allergy to any investigational drug component.
• •Heavy Smoking (\> 5 cigarettes/day); history of drug/alcohol abuse; consumption of caffeine or alcohol within 48 hours before dosing.
• •Blood donation/loss ≥400 mL or transfusion within 12 weeks, or plan to donate during study.
• •Abdominal skin issues that may affect drug injection/observation.
• •Positive for HBV, HCV, HIV, or syphilis.
• •Clinically significant ECG abnormality or TdP risk factors.
• •Any condition judged unsuitable by investigator.
• •CHB Participants:
• •Currently participating in another study, or within 5 half-lives/3 months of the last dose of a previous investigational product.
• •Presence of ascites, gastrointestinal bleeding, hepatic encephalopathy, or varices.
• •History or suspicion of hepatocellular carcinoma (HCC); AFP \> 50 ng/mL.
• •Diagnosed or Suspected cirrhosis within 12 months.
• •History of transplantation, autoimmune diseases, or severe systemic diseases (besides chronic HBV).
• •Use of ASO, siRNA (oligonucleotide therapies), or interferon within 12 months.
• •Major injury/surgery within 6 months, planned surgery during study, or acute infection within 14 days.
• •Allergy to any investigational drug component.
• •Blood donation/loss ≥400 mL or transfusion within 12 weeks, or plan to donate during study.
• •Abdominal skin issues that may affect drug injection/observation.
• •Key laboratory result not suitable for clinical trial.
• •HIV, HCV, or active syphilis infection; uncured hepatitis A, D, or E.
• •Clinically significant ECG abnormality or TdP risk factors.
• •Any condition judged unsuitable by investigator.